Cholestasis in young infants has a varied etiology. There is considerable delay in presentation of cholestatic cases, both in India (average delay of 3 months in referral centers) and Bangladesh (3.5 months 
Introduction:
Jaundice is caused by elevated serum bilirubin concentration. It is apparent in infants when the serum bilirubin value is greater than 4 to 5 mg/dL (68.4 to 85.5 mcmol/L) and in older children at values greater than 2 to 3 mg/dL (34.2 to 51.3 mmol/L). 1,2 Serum total bilirubin is measured in the laboratory as the sum of two components: unconjugated ("indirect") and conjugated ("direct") fractions. The terms "direct" and conjugated hyperbilirubinemia often are used interchangeably. Conjugated hyperbilirubinemia is defined as a conjugated bilirubin concentration greater than 2 mg/dL (34.2 mmol/L) or more than 20% of total bilirubin. It is the biochemical marker of cholestasis used most commonly and defined as perturbation of bile flow. Conjugated hyperbilirubinemia is less common, affecting approximately 1 in 2,500 infants. 3, 4 This condition is never normal at any age, and distinguishing cholestasis from noncholestatic causes of jaundice is crucial. Prolonged hyperbilirubinemia of greater than 2 to 3 weeks duration requires additional investigations. 5 It is paramount to fractionate the bilirubin in infants who have abnormal or prolonged jaundice to identify those who have conjugated hyperbilirubinemia and recognize the disorders that may be amenable to early medical intervention (eg, galactosemia, urinary tract infection) or surgery (eg, biliary atresia, choledochal cyst). 6 In addition, early diagnosis facilitates the institution of necessary nutritional and medical support to promote optimal growth and development. 7 The consequences of infantile cholestasis are profound, resulting in malabsorption, failure to thrive, and deficiencies of fat-soluble vitamins. Cholestatic babies are at special risk for life-threatening bleeding due to vitamin K deficiency. These babies need more calories to maintain growth and also supplementation of vitamins A, D, E and K at diagnosis and thereafter. 8 The Children's Liver Disease Foundation launched an educational program in the United Kingdom in 1993 with the help of the Department of Health to improve the outcome of infantile hepatobiliary diseases. The aim of that campaign was to make certain that all babies who remain jaundiced after 2 weeks of age are tested for conjugated hyperbilirubinemia and referred for timely management. 8 Pilot programs have also been developed in Japan and Taiwan, wherein color cards are given to mothers for early recognition of acholic stools. 9 An awareness campaign is urgently required to improve the outcome in Bangladesh and other countries observed to have such a delay in cholestatic babies referral. 2,10 Materials and Methods: This Prospective study was conducted in the Department of Pediatric Gastroenterology & Nutrition, Bangabandhu Sheikh Mujib Medical University from July 2007 to December 2007. Ethical clearance was taken from the ethical clearance committee before study. Total thirty patients were enrolled in this study. Sampling technique was non probability purposive sampling. Inclusion criteria of patients were infants (2 weeks to 12 months), both sexes, infants with cholestatic jaundice (S, conjugated bilirubin > 2 mg or more than 20% of total bilirubin) persisting beyond 2 weeks of age. Exclusion criteria of patients were age more than 12 months & less than 2 weeks, jaundice due to other causes, seriously ill infants who need referral. A detailed history was obtained from mother of infants with cholestatic jaundice (scleral icterus, dark urine and pale stool) persisting beyond 2 weeks of age and was recorded in a predesigned questionnaire. A thorough physical examination, including examination of the eyes, stool color were observed daily after admission to look for persistent or intermittent nature of icterus and pale stool and examination findings were recorded. Complete blood count and liver function tests (S. bilirubin -total & direct, ALT, ALP, and PT) were done. Urine was tested for non-glucose reducing substances. Ultrasonography of the hepatobiliary system, Hepatobiliary scintigraphy was done after IV administration of 3 mci of mebrofenin (BrIDA), following administration of phenobarbitone (5 mg/Kg/day orally in two divided doses) for at least 5 days. At scintigraphy, absence of radioactivity in the small bowel after 24 hours was considered as absent tracer excretion. Liver biopsy was done in appropriate patients. To find out the causes of neonatal cholestasis, blood examination for HBsAg and TORCH screening, thyroid function test were done. Patients were followed up daily during hospital stay. The management & its response were also monitored and recorded. The short term outcome during hospital stay was noticed. The whole analysis was done with the help of computer using SPSS (Statistical package for social science) program version 10. Continuous variables were summarized as groups or as mean + standard deviation (SD) and categorical data as frequencies and percentages.
For continuous variables differences among groups were analyzed by Analysis Of Variance (ANOVA) test. The chi-square test was applied to compare differences between discrete variables. For multiple comparisons a 'p' value <0.05 was considered statistically significant. Table 1 showed clinical findings in the studied groups. Most of the patients were male, 10 (83%) in BA, 14 (78%) in NH. Only 2 and 4 were female in BA & NH respectively. Out of 12 patients in BA, 11(92%) were term and only 1 was preterm, whereas in NH group, larger number of babies 10(56%) were preterm and 8 (44%) out of 18 babies were term babies, which was statistically significant (p<0.05). Among mothers of NH babies, maternal fever was seen in 5 (28%) subjects and only 2 out of 12 (17%) mothers of BA group gave history of fever. Only 2 mothers in NH had rash and none in BA group. 2 (17%) out of 12 in BA had ascitis and 1 baby had oedema. Similar findings were noticed in NH group too, 2(11.1%) out of 18 had ascitis and 1(5.6%) baby had oedema. Among the patients of biliary atresia out of 12, 11 (91%) had persistent acholic stool and only 1 patient had intermittent acholic stool. Whereas in Neonatal hepatitis group, 15 ( 83%) out of 18 had intermittent acholic stool and 3 (16%) had persistent acholic stool, which was statistically significant (p value < .05 ).
Results:
35 Table 1 Table 3 showed TORCH screening & USG finding of babies with cholestatic jaundice. Among biliary atresia group, 4 (33%) were found to be positive for CMV infection, and only 1 baby was positive for HSV infection. In NH group, 13(72%) babies had positivity for CMV infection and 5 (28%) for HSV infections, which was statistically significant (p value < .05). Out of 30 patients, normal ultrasonic findings came out in 2 (17%) patients of biliary atresia group, and 7 (39%) in NH group. 10 (55%) patients of NH and 5 (42%) patients of BA had shown contracted gall bladder both before and after meal. On the other hand no patient had shown contracted gall bladder after meal in BA, 1 baby among NH showed contracted gall bladder after meal. Choledochal cyst was found in 5 (41.7%) patients of BA group. 
Discussion:
In our study, at presentation, mean age of babies in BA group was 4.13± 2.11SD, where as in NH babies mean age was 3.86 ± 2.11SD. Mean age at onset of jaundice in 2 groups were 3.92 ±2.43 in BA and in NH it was 6.5 ±4.5. In infants with BA, delay in presentation and diagnosis is the single most important factor that results in poor prognosis in developing countries. 1,2 The mean age at presentation to hospital of BA cases in the series by Karim B et al was 3.5 months, 2 though the mean age of onset of jaundice was 5 . 8 days. Matthai J et al 7 reported the mean age at presentation to hospital in their series was 2.9 months, while the mean age at onset of jaundice was 40 days. In the present study, it was found that mean value of birth weight in BA was 2.65±. 13 and in NH babies it was 2.40±.31, which is statistically significant (p-0.013). CMV infection was found to be the commonest cause of neonatal hepatitis. 13 Dick et al 14 suggested idiopathic hepatitis as the main cause of neonatal hepatitis, but their studies antedate the descriptions of recently recognized metabolic causes of cholestasis. On the other hand, advances in preventive medicine may result in the lower incidence of congenital infections compared to idiopathic hepatitis in some recent studies. 15 In our study among biliary atresia group, 4 (33%) were found to be positive for CMV infection, and only 1 baby was positive for HSV infection. In NH group, 13(72%) babies had positivity for CMV infection and 5 (28%) for HSV infections, which was statistically significant (p value <.05). Persistent acholic stools are an important feature of BA. 12, 15 In the study by Karim et al, 13 of 16 infants with BA and 16 of 37 infants with NH/INH had such stools. In BA, during the initial phase of the illness, stools may contain some bile pigment and may not be totally acholic. In that series, intermittent pale-colored stools were observed in 3 of 16 BA cases. 2, 15 In our study, out of 12 patients of Biliary atresia 11 (91%) had persistent acholic stool and only 1 patient had intermittent acholic stool. Whereas in Neonatal hepatitis group, 15 (83%) out of 18 had intermittent acholic stool and 3 (16%) had persistent acholic stool, which is statistically significant (p value <.05). Splenomegaly was found in higher percentage in infants with neonatal hepatitis compared to biliary atresia cases. 16 In contrast, no statistically significant difference was observed when hepatosplenomegaly was compared in 2 studied groups. Mean value for hepatic enlargement in BA were 4.29±1. 
Study limitation:
Number of study population was limited and Gamma GT, Alpha 1 antitrypsin level, Hepatitis C virus could not be done due to financial constraint of parents.
